BIOMAT Database Logo BIOMAT Database Logo

[Correlation of VISTA and PD-L1 expression with the clinicopathological features and prognosis in triple-negative breast cancer]. 2022

B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Objective: To investigate the expression of VISTA and PD-L1 in triple-negative breast cancer (TNBC) and to explore its relationship with clinicopathologic features and prognosis. Methods: Ninety TNBC patients who underwent surgical resections between 2016 to 2018 in Jiangsu Province Hospital were selected. The expression of VISTA and PD-L1 in both tumor cells and immune cells was evaluated by immunohistochemistry, and the relationship with clinicopathologic parameters and prognosis was analyzed. Results: VISTA was expressed in 17.8% (16/90) of the tumors. The expression of VISTA in tumor cells was related to a higher Ki-67 proliferation index (P=0.02) and higher number of tumor-infiltrating lymphocytes (TIL, P<0.01). VISTA was expressed in 71.1% (64/90) of the immune cells and the expression correlated with smaller tumor size (P=0.02), lower T stage (P=0.04), higher number of TIL (P<0.01), higher number of CD8+T cells (P=0.03) and higher Ki-67 proliferation index (P=0.02). PD-L1 was expressed in 17.8% (16/90) of the immune cells and the expression correlated with higher histologic grade (P=0.04), higher Ki-67 proliferation index (P=0.02) and higher number of TIL (P<0.01). VISTA expression was higher in immune cells within TNBC patients than PD-L1 (P<0.01). Among 90 TNBC patients, complete follow-up was obtained in 85 patients, 8 of whom had recurrences or metastasis after surgery, and two patients cases died of recurrences or metastasis. Conclusions: The expression rate of VISTA is higher than that of PD-L1 in TNBC. The expression of VISTA in immune cells predicts a lower T stage. VISTA may act as an effective immunotherapy target.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D060890 B7-H1 Antigen An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION. Antigens, CD274,PD-L1 Protein,Programmed Cell Death 1 Ligand 1 Protein,Programmed Death Ligand 1,B7-H1 Immune Costimulatory Protein,B7H1 Immune Costimulatory Protein,CD274 Antigen,PD-L1 Costimulatory Protein,Programmed Cell Death 1 Ligand 1,Antigen, B7-H1,Antigen, CD274,B7 H1 Antigen,B7 H1 Immune Costimulatory Protein,CD274 Antigens,Costimulatory Protein, PD-L1,PD L1 Costimulatory Protein,PD L1 Protein
D019394 Ki-67 Antigen A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells. Antigen Ki-67,MIB-1 Antigen,Antigen Ki67,Antigen Ki 67,Antigen, Ki-67,Antigen, MIB-1,Ki 67 Antigen,Ki-67, Antigen,Ki67, Antigen,MIB 1 Antigen
D064726 Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN. ER-Negative PR-Negative HER2-Negative Breast Cancer,ER-Negative PR-Negative HER2-Negative Breast Neoplasms,Triple Negative Breast Cancer,Triple-Negative Breast Cancer,Triple-Negative Breast Neoplasm,Breast Cancer, Triple-Negative,Breast Cancers, Triple-Negative,Breast Neoplasm, Triple-Negative,Breast Neoplasms, Triple-Negative,ER Negative PR Negative HER2 Negative Breast Cancer,ER Negative PR Negative HER2 Negative Breast Neoplasms,Triple Negative Breast Neoplasm,Triple-Negative Breast Cancers,Triple-Negative Breast Neoplasms

Related Publications

B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
October 2019, European journal of breast health,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
[Correlation analysis of PD-L1 expression and prognosis in triple-negative breast cancers].
December 2017, Zhonghua bing li xue za zhi = Chinese journal of pathology,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
PD-L1 expression in triple-negative breast cancer.
April 2014, Cancer immunology research,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
January 2021, Annals of translational medicine,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
Correlation of Clinicopathological Features and LGR5 Expression in Triple-Negative Breast Cancer.
June 2020, Annals of diagnostic pathology,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
[Clinicopathological features and prognosis of triple-negative breast cancer].
June 2013, Zhonghua zhong liu za zhi [Chinese journal of oncology],
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer.
January 2018, Annals of clinical and laboratory science,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics.
January 2021, Evidence-based complementary and alternative medicine : eCAM,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer.
January 2016, Journal of Cancer,
B Y Zhai, and Y F Yang, and Y X Gong, and Z D Huang, and G X Song, and Z H Zhang
Retracted: Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics.
January 2023, Evidence-based complementary and alternative medicine : eCAM,
Copied contents to your clipboard!